Latest filings (excl ownership)
8-K
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
30 Sep 24
10-K
2024 FY
Annual report
30 Sep 24
8-K
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors
10 Sep 24
8-K
Entry into a Material Definitive Agreement
10 Sep 24
RW
Registration withdrawal request
10 Sep 24
8-K
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
5 Aug 24
8-K
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
30 Jul 24
S-1/A
IPO registration (amended)
17 Jul 24
S-1
IPO registration
3 Jul 24
8-K
Other Events
30 May 24
10-Q
2024 Q3
Quarterly report
15 May 24
8-K
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
7 May 24
8-K
Incannex Healthcare Inc. Quarterly Update, Q1 2024
16 Apr 24
8-K
Departure of Directors or Certain Officers
5 Mar 24
8-K
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
28 Feb 24
8-K
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
16 Feb 24
10-Q
2024 Q2
Quarterly report
14 Feb 24
8-K
Other Events
1 Feb 24
8-K
Other Events
24 Jan 24
8-K
Other Events
18 Jan 24
8-K
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
17 Jan 24
8-K
Clarion Clinics Receives Ethics Board Endorsment for the First Dedicated Psychedelic-assisted Therapy Clinic In Australia
22 Dec 23
S-8
Registration of securities for employees
20 Dec 23
8-K
Changes in Registrant's Certifying Accountant
15 Dec 23
EFFECT
Notice of effectiveness
1 Dec 23
8-K
Entry into a Material Definitive Agreement
29 Nov 23
POS AM
Prospectus update (post-effective amendment)
29 Nov 23
15-12G
Securities registration termination
29 Nov 23
25-NSE/A
Exchange delisting (amended)
29 Nov 23
25-NSE
Exchange delisting
28 Nov 23
6-K
Report of Foreign Private Issuer
24 Nov 23
6-K
Report of Foreign Private Issuer
20 Nov 23
6-K
Computershare will be appointed US Transfer Agent and Registrar to facilitate Transfer Capabilities for Nasdaq-listed shares
16 Nov 23
6-K
Report of Foreign Private Issuer
16 Nov 23
6-K
Not for release to US wire services or distribution in the United States
16 Nov 23
6-K
Results of Scheme Meetings
8 Nov 23
6-K
Report of Foreign Private Issuer
7 Nov 23
20-F
2023 FY
Annual report (foreign)
31 Oct 23
6-K
Incannex Healthcare September 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
26 Oct 23
6-K
Voting Update for Incannex to Redomicile to United States and Trade on Nasdaq Securities Exchange
18 Oct 23
Latest ownership filings
5
Joseph Swan
2 Aug 24
4
Troy Valentine
21 Dec 23
4
Peter Widdows
21 Dec 23
4
Joel Latham
21 Dec 23
4
George Anastassov
21 Dec 23
4
Robert Clark
21 Dec 23
3/A
Robert Clark
8 Dec 23
3
George Anastassov
6 Dec 23
3
Troy Valentine
6 Dec 23
3
Robert Clark
6 Dec 23
3
Peter Widdows
6 Dec 23
3
Madhukar Bhalla
6 Dec 23
3
Lekhram Changoer
6 Dec 23
3
Joseph Swan
6 Dec 23
3
Joel Latham
6 Dec 23